SCHEMBL14901137

SCHEMBL14901137

N#Cc1cnc2ccc(Cl)nc2n1

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RPS6KA5 O75582 1/20 0.34
RPS6KA4 O75676 1/20 0.34
CHEK1 O14757 2/20 0.32
ALDH1A1 P00352 1/20 0.32
CRHBP P24387 1/20 0.32
CRHR2 Q13324 1/20 0.32
HPGDS O60760 1/20 0.31
MAPK1 P28482 1/20 0.30
PIK3CA P42336 1/20 0.30
MAPK8 P45983 1/20 0.30
MAPK9 P45984 1/20 0.30
MAPK10 P53779 1/20 0.30
PSMB8 P28062 2/20 0.30
PSMB5 P28074 1/20 0.30
NQO1 P15559 1/20 0.30
CSNK1A1 P48729 1/20 0.30
CLK4 Q9HAZ1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9978592 0.82 ALDH1A1 (0.43) RPS6KA5RPS6KA4ALDH1A1CRHBPCRHR2
SCHEMBL14901136 0.79 SOS2 (0.32) CHEK1HPGDSMAPK1PIK3CAMAPK8
SCHEMBL14901200 0.77 ALDH1A1 (0.32) ALDH1A1
SCHEMBL4686457 0.72 CDK2 (0.39) ALDH1A1
SCHEMBL14901108 0.72 MAPK1 (0.36) ALDH1A1CRHBPCRHR2MAPK1
SCHEMBL3638928 0.72 PIK3CD (0.42) ALDH1A1CRHBPCRHR2MAPK1PIK3CA
SCHEMBL21727979 0.72 ALDH1A1 (0.38) ALDH1A1CRHBPCRHR2PIK3CAMAPK8
SCHEMBL20951862 0.71 HRH4 (0.44) ALDH1A1MAPK1PIK3CAPSMB8PSMB5
SCHEMBL16125091 0.70 PDGFRB (0.46) CHEK1MAPK1PIK3CAMAPK8MAPK9
SCHEMBL21856180 0.69 ALDH1A1 (0.42) RPS6KA5RPS6KA4ALDH1A1CRHBPCRHR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10004733-B2 2018-06-26 US disclosed
US-10004733-B2 2018-06-26 US disclosed
US-20160235744-A1 SUBSTITUTED PYRIDO[2,3-b]PYRAZINES AS FGFR KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2016-08-18 US disclosed
US-20160235744-A1 SUBSTITUTED PYRIDO[2,3-b]PYRAZINES AS FGFR KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2016-08-18 US disclosed
WO-2013061080-A1 ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES ASTEX THERAPEUTICS LIMITED (GB) 2013-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10004733-B2 SDHB, SDHA, NDUFS5 RPS6KA5 2069/4885RPS6KA4 3579/4885CHEK1 2273/4885
US-20160235744-A1 SUBSTITUTED PYRIDO[2,3-b]PYRAZINES AS FGFR KINASE INHIBITORS FGFR1, FGFR2, FGFR3 RPS6KA5 325/4885RPS6KA4 575/4885CHEK1 276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.